Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression

HIV Medicine

Volumn 11, Issue 3, 2010, Pages 216-224

  Cambiano, V ^a   Lampe, F C ^a   Rodger, A J ^a,b   Smith, C J ^a   Geretti, A M ^b   Lodwick, R K ^a   Holloway, J ^b   Johnson, M ^b   Phillips, A N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral drugs; Drug adherence; HIV infection; Prescription; Viral rebound

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; CONFOUNDING VARIABLE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; REBOUND; UNITED KINGDOM; VIRUS LOAD; VIRUS REACTIVATION;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; DRUG PRESCRIPTIONS; FEMALE; HIV INFECTIONS; HUMANS; LONDON; MALE; MEDICATION ADHERENCE; PREDICTIVE VALUE OF TESTS; RECURRENCE; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 75649152847     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00771.x     Document Type: Article

References (49)

1. Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996, 124:984-994.
2. Yeni PG, Hammer SM, Carpenter CC. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002, 288:222-235.
3. Parkin NT, Deeks SG, Wrin MT. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. AIDS 2000, 14:2877-2887.
4. O'Brien WA, Hartigan PM, Martin D. Changes in plasma HIV-1 RNA and CD4+lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 1996, 334:426-431.
5. Mocroft A, Ruiz L, Reiss P. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003, 17:1741-1751.
6. Smith CJ, Phillips AN, Hill T. The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study. J Infect Dis 2005, 192:1387-1397.
7. Benzie AA, Bansi LK, Sabin CA. Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. AIDS 2007, 21:1423-1430.
8. Le Moing V, Chene G, Carrieri MP. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002, 16:21-29.
9. Antinori A, Cozzi-Lepri A, Ammassari A. Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir Ther 2004, 9:291-296.
10. Phillips AN, Staszewski S, Lampe F. Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis 2002, 186:1086-1091.
11. Phillips AN, Ledergerber B, Horban A. Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. AIDS 2004, 18:1795-1804.
12. Bansi LK, Benzie AA, Phillips AN. Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS 2008, 22:349-356.
13. Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001, 15:2109-2117.
14. Bangsberg DR, Hecht FM, Charlebois ED. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000, 14:357-366.
15. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002, 34:1115-1121.
16. Liu H, Miller LG, Hays RD. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr 2006, 41:315-322.
17. Parruti G, Manzoli L, Toro PM. Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: predictors and impact on virologic response and relapse. AIDS Patient Care STDS 2006, 20:48-56.
18. Paterson DL, Swindells S, Mohr J. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21-30.
19. Montaner JS, Reiss P, Cooper D. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998, 279:930-937.
20. Bangsberg DR, Charlebois ED, Grant RM. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003, 17:1925-1932.
21. McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis 2001, 33:700-705.
22. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr 2004, 35:261-268.
23. Hogg RS, Heath K, Bangsberg D. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002, 16:1051-1058.
24. Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002, 30:105-110.
25. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med 2003, 139:810-816.
26. Descamps D, Flandre P, Calvez V. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) study team. JAMA 2000, 283:205-211.
27. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998, 279:1977-1983.
28. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006, 43:939-941.
29. Maggiolo F, Ravasio L, Ripamonti D. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005, 40:158-163.
30. Gulick RM. Adherence to antiretroviral therapy: how much is enough? Clin Infect Dis 2006, 43:942-944.
31. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 2007, 45:4-8.
32. Martin M, Del CE, Codina C. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses 2008, 24:1263-1268.
33. Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol 2004, 57:1107-1110.
34. Miller LG, Hays RD. Measuring adherence to antiretroviral medications in clinical trials. HIV Clin Trials 2000, 1:36-46.
35. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000, 23:360-361.
36. Kitahata MM, Reed SD, Dillingham PW. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS 2004, 15:803-810.
37. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr 2006, 43((Suppl. 1)):S79-S87.
38. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997, 50:105-116.
39. Gross R, Yip B, Lo RV. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis 2006, 194:1108-1114.
40. Sabin CA, Lampe FC, Chaloner C. An audit of antiretroviral treatment use in HIV-infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use. HIV Med 2003, 4:87-93.
41. Feldman HI, Hackett M, Bilker W, Strom BL. Potential utility of electronic drug compliance monitoring in measures of adverse outcomes associated with immunosuppressive agents. Pharmacoepidemiol Drug Saf 1999, 8:1-14.
42. Gardner EM, Burman WJ, Maravi ME, Davidson AJ. Selective drug taking during combination antiretroviral therapy in an unselected clinic population. J Acquir Immune Defic Syndr 2005, 40:294-300.
43. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004, 159:702-706.
44. Harrigan PR, Hogg RS, Dong WW. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005, 191:339-347.
45. de la Rosa R, Ruiz-Mateos E, Rubio A. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy. J Antimicrob Chemother 2004, 53:95-101.
46. Bisson GP, Gross R, Bellamy S. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 2008, 5:e109.
47. Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr 2006, 43((Suppl. 1)):S149-S155.
48. Lampe FC, Smith CJ, Madge S. Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med 2007, 167:692-700.
49. Hammer SM, Saag MS, Schechter M. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006, 296:827-843.